

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following statements is true regarding the CDK4/6 inhibitor abemaciclib?
 - It is effective for patients with CNS metastases
 - It does not demonstrate single-agent activity
 - It is administered on a continuous schedule
 - All of the above
 - Both a and c
 - Both b and c
- Which agent has demonstrated activity in patients with ER-positive advanced breast cancer and ESR1 mutations?
 - Endoxifen
 - Elacestrant
 - Fulvestrant
 - All of the above
 - Both a and b
- Side effects associated with alpelisib include _____.
 - Diarrhea
 - Hyperglycemia
 - Rash
 - All of the above
- A retrospective study by Goetz and colleagues demonstrated that for patients with ER-positive mBC and disease progression on first-line CDK4/6 inhibitors, better outcomes were obtained with everolimus/exemestane compared to single-agent hormonal therapy.
 - True
 - False
- The mTORC1/2 inhibitor TAK-228 is being investigated in combination with tamoxifen on the Phase II ANETT trial for patients with ER-positive breast cancer in the _____ setting.
 - Neoadjuvant
 - Adjuvant
 - Both a and b
- Which of the following statements is true regarding elacestrant in the management of ER-positive breast cancer?
 - It is administered intramuscularly
 - It is a SERD
 - It has demonstrated efficacy after disease progression on fulvestrant
 - Both a and b
 - Both b and c
- The SOLAR-1 trial comparing the PI3-kinase inhibitor alpelisib with fulvestrant to fulvestrant alone demonstrated a significant improvement in progression-free survival with alpelisib for patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer and _____.
 - A PIK3CA mutation
 - No PIK3CA mutation
 - Both a and b
- Patients on the TAILORx trial with HR-positive, HER2-negative, node-negative breast cancer and a RS of 11 to 25 experienced a significant benefit with chemoendocrine therapy compared to endocrine therapy alone.
 - True
 - False
- In the Phase III PALOMA-3 trial, the addition of palbociclib to fulvestrant for HR-positive advanced breast cancer demonstrated a longer overall survival for patients with sensitivity to previous endocrine therapy.
 - True
 - False
- The Phase III MONALEESA-7 trial demonstrated a significant improvement in overall survival with the addition of ribociclib to endocrine therapy for _____ patients with HR-positive, HER2-negative advanced breast cancer.
 - Premenopausal
 - Postmenopausal